Vor Biopharma Inc (VOR NASDAQ) stock market data APIs
$19.9336
0.5(2.5%)
as of November 4, 2026
Try our APIs with
free plan!
Vor Biopharma Inc Financial Data Overview
Price chart is built with
Anychart
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Prev. Close
19.9336
Open
20.4323
High
20.6355
Low
19.591
52 wk Range
6.5-26
Market Cap
1 220 M
P/E Ratio
0.064
Shares Outstanding
61 434 K
EPS
-0.9
Beta
1.827
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Vor Biopharma Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Vor Biopharma Inc data using free add-ons & libraries
Get Vor Biopharma Inc Fundamental Data
Vor Biopharma Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -147 584 000
- Earnings Per Share: 310
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-10-30
- EPS/Forecast: -0.81
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Vor Biopharma Inc News
New
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
Vor Biopharma Annualized eGFR slope of -0.6 vs. -5.7 mL/min/1.73 m²/year for placebo, a 5.1 mL/min/1.73 m²/year treatment difference (p<0.001) 89% and 81% reductions in risk of confirmed ≥30% an...
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Biopharma BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on Octob...
Durable MG Responses From Telitacicept Could Be A Game Changer For Vor Biopharma (VOR)
In September 2026, Vor Biopharma reported a post hoc analysis from a China-based Phase 3 trial showing that telitacicept produced deep, durable clinical responses and was generally well tolerated over...
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
Vor Biopharma More than 94% of participants achieved a ≥5-point MG-ADL improvement at Week 48 42% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48...
Get Vor Biopharma Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.